Alembic Limited (ALEMBICLTD.NS)
INR 97.91
(2.59%)
INR 97.91
(2.59%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 66.9 Million INR | 819.35% |
| 2022 | -9.3 Million INR | 20.61% |
| 2021 | -11.71 Million INR | 79.12% |
| 2020 | -56.1 Million INR | 90.37% |
| 2019 | -582.72 Million INR | -3704.2% |
| 2018 | -15.31 Million INR | -190.95% |
| 2017 | 16.84 Million INR | 187.66% |
| 2016 | -19.21 Million INR | 17.91% |
| 2015 | -23.4 Million INR | 11.43% |
| 2014 | -26.43 Million INR | -112.83% |
| 2013 | 206.05 Million INR | -13.5% |
| 2012 | 238.21 Million INR | -87.28% |
| 2011 | 1.87 Billion INR | 180.57% |
| 2010 | 667.33 Million INR | -82.65% |
| 2009 | 3.84 Billion INR | -16.23% |
| 2008 | 4.59 Billion INR | 13.39% |
| 2007 | 4.04 Billion INR | 120.4% |
| 2006 | 1.83 Billion INR | 2.69% |
| 2005 | 1.78 Billion INR | -11.41% |
| 2004 | 2.01 Billion INR | 1.73% |
| 2003 | 1.98 Billion INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | 463.54 Million INR | 5084.4% |
| 2023 FY | 66.9 Million INR | 819.35% |
| 2023 Q2 | 31.2 Million INR | -93.27% |
| 2023 Q3 | 46.3 Million INR | 48.4% |
| 2023 Q4 | 66.9 Million INR | 44.49% |
| 2022 Q2 | -9.6 Million INR | -103.47% |
| 2022 Q4 | -9.3 Million INR | -101.88% |
| 2022 FY | -9.3 Million INR | 20.61% |
| 2022 Q1 | 276.8 Million INR | 2462.98% |
| 2022 Q3 | 495 Million INR | 5256.25% |
| 2021 Q3 | 736.2 Million INR | 2786.86% |
| 2021 FY | -11.71 Million INR | 79.12% |
| 2021 Q2 | -27.4 Million INR | -112.18% |
| 2021 Q4 | -11.71 Million INR | -101.59% |
| 2021 Q1 | 224.98 Million INR | 501.02% |
| 2020 Q2 | -29.7 Million INR | -102.65% |
| 2020 Q4 | -56.1 Million INR | -105.89% |
| 2020 Q1 | 1.12 Billion INR | 292.25% |
| 2020 FY | -56.1 Million INR | 90.37% |
| 2020 Q3 | 953.1 Million INR | 3309.09% |
| 2019 Q2 | -19.9 Million INR | -104.38% |
| 2019 Q1 | 454.7 Million INR | 3068.4% |
| 2019 Q3 | 644.9 Million INR | 3340.7% |
| 2019 Q4 | -582.72 Million INR | -190.36% |
| 2019 FY | -582.72 Million INR | -3704.2% |
| 2018 FY | -15.31 Million INR | -190.95% |
| 2018 Q4 | -15.31 Million INR | 0.0% |
| 2017 FY | 16.84 Million INR | 187.66% |
| 2017 Q4 | 16.84 Million INR | 0.0% |
| 2016 Q4 | -23.1 Million INR | 0.0% |
| 2016 FY | -19.21 Million INR | 17.91% |
| 2015 Q3 | 394.4 Million INR | 1073.83% |
| 2015 FY | -23.4 Million INR | 11.43% |
| 2015 Q4 | -23.4 Million INR | -105.94% |
| 2015 Q2 | -40.5 Million INR | -127.23% |
| 2015 Q1 | 148.73 Million INR | 662.75% |
| 2014 Q3 | 30 Million INR | 214.94% |
| 2014 Q4 | -26.43 Million INR | -188.1% |
| 2014 FY | -26.43 Million INR | -112.83% |
| 2014 Q1 | 9.6 Million INR | -95.34% |
| 2014 Q2 | -26.1 Million INR | -371.71% |
| 2013 Q2 | 371.8 Million INR | 2830.33% |
| 2013 Q4 | 206.05 Million INR | 1437.73% |
| 2013 FY | 206.05 Million INR | -13.5% |
| 2013 Q1 | 12.68 Million INR | -94.67% |
| 2013 Q3 | 13.4 Million INR | -96.4% |
| 2012 FY | 238.21 Million INR | -87.28% |
| 2012 Q2 | -12.6 Million INR | 0.0% |
| 2012 Q3 | 12.6 Million INR | 200.0% |
| 2012 Q4 | 238.21 Million INR | 1790.59% |
| 2011 Q4 | 1.87 Billion INR | 0.0% |
| 2011 FY | 1.87 Billion INR | 180.57% |
| 2010 FY | 667.33 Million INR | -82.65% |
| 2009 FY | 3.84 Billion INR | -16.23% |
| 2008 Q4 | 4.59 Billion INR | 0.0% |
| 2008 FY | 4.59 Billion INR | 13.39% |
| 2007 FY | 4.04 Billion INR | 120.4% |
| 2006 FY | 1.83 Billion INR | 2.69% |
| 2005 FY | 1.78 Billion INR | -11.41% |
| 2004 FY | 2.01 Billion INR | 1.73% |
| 2003 FY | 1.98 Billion INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 98.269% |
| Hester Biosciences Limited | 2.29 Billion INR | 97.08% |
| Aarti Drugs Limited | 5.54 Billion INR | 98.794% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 97.439% |
| Albert David Limited | -278.36 Million INR | 124.033% |
| Alkem Laboratories Limited | -1.6 Billion INR | 104.157% |
| Bafna Pharmaceuticals Limited | 229.93 Million INR | 70.905% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 97.972% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 462.68% |
| Brooks Laboratories Limited | 49.48 Million INR | -35.192% |
| Eris Lifesciences Limited | 13.8 Billion INR | 99.515% |
| FDC Limited | -57.75 Million INR | 215.84% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 102.353% |
| Gufic Biosciences Limited | 3.19 Billion INR | 97.906% |
| Hikal Limited | 7.96 Billion INR | 99.16% |
| Ind-Swift Limited | 9.5 Billion INR | 99.296% |
| Innova Captab Limited | 2.33 Billion INR | 97.133% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 106.075% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 104.813% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 99.753% |
| Lincoln Pharmaceuticals Limited | -127.63 Million INR | 152.414% |
| Lupin Limited | 19.38 Billion INR | 99.655% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 93.144% |
| Medico Remedies Limited | 78.67 Million INR | 14.969% |
| Morepen Laboratories Limited | -231.17 Million INR | 128.939% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 98.913% |
| Orchid Pharma Limited | -1.31 Billion INR | 105.092% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 102.849% |
| RPG Life Sciences Limited | -364.7 Million INR | 118.344% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | 44.268% |
| Sigachi Industries Limited | 859.94 Million INR | 92.22% |
| Solara Active Pharma Sciences Limited | 10.03 Billion INR | 99.333% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | 53.854% |
| Themis Medicare Limited | 764.96 Million INR | 91.254% |
| Unichem Laboratories Limited | 931.91 Million INR | 92.821% |
| Vaishali Pharma Limited | 119.13 Million INR | 43.845% |
| Wanbury Limited | 1.1 Billion INR | 93.95% |
| Windlas Biotech Limited | -273.04 Million INR | 124.502% |
| ZIM Laboratories Limited | 983.6 Million INR | 93.198% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 101.611% |
| Ipca Laboratories Limited | 11.41 Billion INR | 99.414% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 100.092% |
| Venus Remedies Limited | -267.7 Million INR | 124.991% |
| Sakar Healthcare Limited | 790.93 Million INR | 91.542% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 98.189% |
| Divi's Laboratories Limited | -39.77 Billion INR | 100.168% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 101.335% |
| Mankind Pharma Limited | -1.74 Billion INR | 103.826% |
| Sequent Scientific Limited | 4.17 Billion INR | 98.399% |
| Laurus Labs Limited | 24.35 Billion INR | 99.725% |
| Neuland Laboratories Limited | -214.05 Million INR | 131.253% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 97.629% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 101.561% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 98.29% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 126.89% |
| Wockhardt Limited | 18.27 Billion INR | 99.634% |
| Bal Pharma Limited | 1.26 Billion INR | 94.705% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 99.482% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 105.778% |
| Par Drugs and Chemicals Limited | -366.53 Million INR | 118.252% |
| Caplin Point Laboratories Limited | -5.5 Billion INR | 101.215% |
| Shilpa Medicare Limited | 9.06 Billion INR | 99.262% |
| Valiant Laboratories Limited | 649.9 Million INR | 89.706% |
| Ajanta Pharma Limited | -954.9 Million INR | 107.006% |
| Aarey Drugs & Pharmaceuticals Limited | 297.57 Million INR | 77.519% |
| Granules India Limited | 9.28 Billion INR | 99.28% |
| Medicamen Biotech Limited | 160.31 Million INR | 58.27% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -44.771% |
| Piramal Enterprises Limited | 491.39 Billion INR | 99.986% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 99.79% |
| NATCO Pharma Limited | -5.81 Billion INR | 101.15% |
| Suven Life Sciences Limited | -1.63 Billion INR | 104.098% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 96.539% |
| Strides Pharma Science Limited | 23.25 Billion INR | 99.712% |
| Indoco Remedies Limited | 6.47 Billion INR | 98.967% |
| Alpa Laboratories Limited | 35.36 Million INR | -89.181% |
| Lasa Supergenerics Limited | 205.79 Million INR | 67.493% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 107.103% |